IL161590A0 - Poxvirus containing formulations and process for preparing stable poxvirus containing compositions - Google Patents

Poxvirus containing formulations and process for preparing stable poxvirus containing compositions

Info

Publication number
IL161590A0
IL161590A0 IL16159002A IL16159002A IL161590A0 IL 161590 A0 IL161590 A0 IL 161590A0 IL 16159002 A IL16159002 A IL 16159002A IL 16159002 A IL16159002 A IL 16159002A IL 161590 A0 IL161590 A0 IL 161590A0
Authority
IL
Israel
Prior art keywords
poxvirus containing
poxvirus
preparing stable
freeze
formulations
Prior art date
Application number
IL16159002A
Other languages
English (en)
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161590(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of IL161590A0 publication Critical patent/IL161590A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IL16159002A 2001-12-10 2002-11-28 Poxvirus containing formulations and process for preparing stable poxvirus containing compositions IL161590A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10
PCT/EP2002/013434 WO2003053463A2 (en) 2001-12-10 2002-11-28 Poxvirus-containing compositions and process for their preparation

Publications (1)

Publication Number Publication Date
IL161590A0 true IL161590A0 (en) 2004-09-27

Family

ID=8160885

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16159002A IL161590A0 (en) 2001-12-10 2002-11-28 Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
IL161590A IL161590A (en) 2001-12-10 2004-04-22 Poxvirus containing formulations, methods for preparing stable poxvirus containing compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161590A IL161590A (en) 2001-12-10 2004-04-22 Poxvirus containing formulations, methods for preparing stable poxvirus containing compositions and uses thereof

Country Status (22)

Country Link
US (1) US7094412B2 (xx)
EP (1) EP1418942B1 (xx)
JP (1) JP4439263B2 (xx)
KR (1) KR20040074067A (xx)
CN (1) CN1296096C (xx)
AT (1) ATE300954T1 (xx)
AU (1) AU2002361962A1 (xx)
BR (1) BR0214822A (xx)
CA (1) CA2467365C (xx)
DE (1) DE60205388T2 (xx)
DK (1) DK1418942T3 (xx)
EA (1) EA006880B1 (xx)
ES (1) ES2247414T3 (xx)
HK (1) HK1071295A1 (xx)
HU (1) HUP0402179A3 (xx)
IL (2) IL161590A0 (xx)
MX (1) MXPA04005577A (xx)
NO (1) NO20042958L (xx)
NZ (1) NZ533302A (xx)
PL (1) PL213326B1 (xx)
UA (1) UA78738C2 (xx)
WO (1) WO2003053463A2 (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DK1434858T4 (en) 2002-09-05 2019-04-01 Bavarian Nordic As PROCEDURE FOR AMPLIFICATION OF A POXVIRUS UNDER SERUM-FREE CONDITIONS
CN1207005C (zh) * 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
EP2152862A1 (en) 2007-05-14 2010-02-17 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
JP5307801B2 (ja) * 2007-05-18 2013-10-02 メディミューン・エルエルシー 凍結乾燥フォームによる生物活性材料の防腐
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
NZ603431A (en) 2010-05-21 2014-06-27 Zoetis Llc Parapoxvirus vectors containing rabies virus antigen
AU2011281229A1 (en) 2010-07-20 2013-01-24 Zoetis Llc Parapoxvirus vectors
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP2872172B1 (en) 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2018270375A1 (en) * 2017-05-15 2019-10-31 Bavarian Nordic A/S Stable virus-containing composition
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
IL271558B2 (en) 2017-06-21 2024-01-01 Transgene A vaccine tailored to the individual
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7437385B2 (ja) 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
US20210386807A1 (en) 2018-10-30 2021-12-16 The University Of Tokyo Oncolytic virus for cancer therapy
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As The compounds that improve the stability of the smallpox virus
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (xx)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (xx) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
WO1998013500A2 (en) * 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
HUP0402179A2 (hu) 2005-01-28
EA200400796A1 (ru) 2004-12-30
DK1418942T3 (da) 2005-11-28
HUP0402179A3 (en) 2012-09-28
MXPA04005577A (es) 2005-04-19
WO2003053463A3 (en) 2004-03-04
CN1602205A (zh) 2005-03-30
PL213326B1 (pl) 2013-02-28
JP4439263B2 (ja) 2010-03-24
IL161590A (en) 2009-06-15
DE60205388T2 (de) 2006-03-30
HK1071295A1 (en) 2005-07-15
JP2005513109A (ja) 2005-05-12
KR20040074067A (ko) 2004-08-21
PL369954A1 (en) 2005-05-02
CA2467365A1 (en) 2003-07-03
WO2003053463A2 (en) 2003-07-03
CN1296096C (zh) 2007-01-24
AU2002361962A1 (en) 2003-07-09
EA006880B1 (ru) 2006-04-28
ATE300954T1 (de) 2005-08-15
US20050019349A1 (en) 2005-01-27
DE60205388D1 (de) 2005-09-08
BR0214822A (pt) 2004-12-14
CA2467365C (en) 2012-11-20
UA78738C2 (en) 2007-04-25
EP1418942A2 (en) 2004-05-19
EP1418942B1 (en) 2005-08-03
NZ533302A (en) 2005-11-25
ES2247414T3 (es) 2006-03-01
US7094412B2 (en) 2006-08-22
NO20042958L (no) 2004-07-09

Similar Documents

Publication Publication Date Title
HK1071295A1 (en) Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
IL159724A0 (en) A nitrogen oxide generating composition for treatment of nail infections
WO2004060059A3 (en) Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
MY129263A (en) Vaccine composition
WO2001070132A3 (en) Injectable and swellable microspheres for dermal augmentation
MXPA01006917A (es) Composicion topica que comprende n-acetilaldosaminas o acidos n-acetilaminos.
CN110339083B (zh) 一种寡肽修复精华液及其使用方法
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
AP1521A (en) Method for the preservation of viruses and mycoplasma.
CA2336542A1 (en) Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them
GR1002451B (el) Αντιφλεγμονωδεις συνθεσεις που εχουν ως βαση ενεργα συστατικα ορισμενων βοτανων χρησιμοποιουμενες για σκοπους ιατρικους και κτηνιατρικους, και μεθοδοι παρασκευης φαρμακων και σκευασματων για τους παραπανω σκοπους.
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
CN101062050A (zh) 一种基于一氧化氮的新型生发产品及其制备方法
GEP20053497B (en) Compositions for Enhanced Acaricidal Activity
WO2003016544A1 (fr) Procede d'elaboration d'acide 1,4-dihydroxy-2-naphtoique
WO2004080415A3 (en) Gel composition and method for treatment of vaginal infections
CN104606101A (zh) 一种辣木面膜
MXPA02004701A (es) Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
CN1331968A (zh) 一种中药牙膏
BR0008739A (pt) Composições de liberação controlada debeta-histina
ITRM20010438A1 (it) Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof